nct_id: NCT05385549
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-05-23'
study_start_date: '2022-09-07'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Imatinib Mesylate'
long_title: A Phase 2 Study of 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal
  Stromal Tumor With a High Risk of Recurrence Following Surgical Resection
last_updated: '2025-08-08'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Asan Medical Center
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 35
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. Age 20 years or older, at the time of acquisition of informed consent
- "2. Histologically confirmed GIST with CD117(+), DOG-1(+), or mutation in KIT or\
  \ PDGFR\u03B1 gene"
- 3. (1) Completely resected localized GIST (R0 resection) within 12 weeks prior to
  the start of the adjuvant imatinib.
- (2) After complete resection(R0 resection), High risk GIST according to Modified
  NIH criteria and ongoing adjuvant imatinib treatment.
- 4\) High risk GIST according to Modified NIH criteria,
- 1. Tumor rupture according to Nishida classification or
- 2. tumor size \>10cm and mitosis \>10/50 HPF 5) Eastern Cooperative Oncology Group
  (ECOG) performance status 0 \~ 2 6) Adequate bone marrow, hepatic, renal, and other
  organ functions, before adjuvant imatinib treatment
- '* Neutrophil \>1,500/mm3'
- '* Platelet \> 100,000/mm3'
- '* Hemoglobin \>8.0 g/dL'
- '* Total bilirubin \< 1.5 x upper limit of normal (ULN)'
- '* AST/ALT \< 2.5 x ULN'
- '* Creatinine \<1.5 x ULN 7) Provision of a signed written informed consent'
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Women of child-bearing potential who are pregnant or breast feeding
- Exclude - 2. Women or men who are not willing to use effective contraception entering
  the study period or until at least 3 months after the last study drug administration.
- "Exclude - 3. If any of the following applies within \u2264 6 months prior to starting\
  \ study enrollment : Myocardial Infarction, severe instable angina, coronary/peripheral\
  \ bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic\
  \ attack, treatment required severe arrhythmia."
- Exclude - 4. Uncontrolled infection
- Exclude - 5. Acute and chronic liver disease and all chronic liver impairment.(But
  Patients with stable chronic hepatitis B are eligible)
- Exclude - 6. Patients who had reduced the dose of imatinib to less than 300 mg/day
  due to toxicity.
- Exclude - 7. Acute, or chronic medical or psychiatric condition or laboratory abnormality
  such as active uncontrolled infection that difficult to study participation in the
  judgment of the investigator
- Exclude - 8. Known diagnosis of HIV infection (HIV testing is not mandatory).
- Exclude - 9. History of another primary malignancy that is currently clinically
  significant or currently requires active intervention.
- Exclude - 10. Alcohol or substance abuse disorder.
- "Exclude - 11. The patients with PDGFR\u03B1 D842V mutation"
short_title: 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal
  Tumor With a High Risk
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Asan Medical Center
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: In this study, the investigators aim to investigate the efficacy and safety
  of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined
  by Nishida classification or those with a tumor size 10cm or larger and a mitotic
  index of 10/50HPFs or higher.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 5 years of adjuvant imatinib treatment
      arm_internal_id: 0
      arm_description: 5 years of adjuvant imatinib treatment
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Imatinib Mesylate'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=20'
          disease_status:
          - Localized
          oncotree_primary_diagnosis: Gastrointestinal Stromal Tumor
      - and:
        - or:
          - genomic:
              hugo_symbol: KIT
              variant_category: Mutation
          - genomic:
              hugo_symbol: "PDGFR\u03B1"
              variant_category: Mutation
        - and:
          - genomic:
              hugo_symbol: "PDGFR\u03B1"
              variant_category: '!Mutation'
